Abstract
Introduction: We report our experience in treating patients with primary breast extranodal marginal zone lymphoma of mucosa-associated lymphoid tissue (MALT)to better elucidate the natural history and optimal treatment approach for these patients. Patients and Methods: Patients with localized primary breast MALT lymphoma treated between 1995 and 2016 were included. Disease-related endpoints including progression-free survival (PFS)were analyzed. Results: Eleven patients met inclusion criteria; all patients were women with a median age of 62 years (range, 42-75 years). Most (73%)patients presented with stage I disease, and most (73%)patients were treated initially treated with radiation therapy (RT). Local control following RT was 100%; all patients with progression following RT experienced distant relapse. Additionally, none of the 3 patients treated with ultra-low-dose RT (4 Gy)experienced subsequent progression (local or distant). Six (55%)patients progressed after initial therapy, of whom 5 received initial RT; the 5-year PFS after initial therapy was 60%. Salvage systemic therapy was utilized in all patients with progression, with 5 of 6 patients receiving single-agent rituximab. Of the patients treated with salvage therapy, only 1 experienced second relapse, with a 5-year PFS of 100% after salvage systemic therapy. With a median follow-up of 8 years, there were no deaths in the cohort. Conclusions: Patients with primary breast MALT lymphoma achieve excellent outcomes. Initial RT affords local control, and although subsequent distant progression is common, salvage rituximab yields high rates of PFS.
Original language | English (US) |
---|---|
Pages (from-to) | 244-250 |
Number of pages | 7 |
Journal | Clinical Lymphoma, Myeloma and Leukemia |
Volume | 19 |
Issue number | 4 |
DOIs | |
State | Published - Apr 2019 |
Keywords
- Breast cancer
- MALT lymphoma
- Observation
- Radiotherapy
- Rituximab
ASJC Scopus subject areas
- Hematology
- Oncology
- Cancer Research